Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more
Scisparc Ltd (SPRC) - Total Liabilities
Latest total liabilities as of September 2025: $5.22 Million USD
Based on the latest financial reports, Scisparc Ltd (SPRC) has total liabilities worth $5.22 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Scisparc Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Scisparc Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Scisparc Ltd Competitors by Total Liabilities
The table below lists competitors of Scisparc Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cyanotech Corporation
NASDAQ:CYAN
|
USA | $15.96 Million |
|
Jiankun International Bhd
KLSE:8923
|
Malaysia | RM46.38 Million |
|
Raptis Group Ltd
AU:RPG
|
Australia | AU$62.52K |
|
Aclarion Inc
NASDAQ:ACON
|
USA | $699.75K |
|
Archies Limited
NSE:ARCHIES
|
India | ₹644.22 Million |
|
Drago entertainment S.A.
WAR:DGE
|
Poland | zł2.25 Million |
|
HELIX Resources Ltd
AU:HLX
|
Australia | AU$439.36K |
Liability Composition Analysis (2006–2024)
This chart breaks down Scisparc Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scisparc Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scisparc Ltd (2006–2024)
The table below shows the annual total liabilities of Scisparc Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.41 Million | -11.72% |
| 2023-12-31 | $1.59 Million | -61.62% |
| 2022-12-31 | $4.16 Million | +134.14% |
| 2021-12-31 | $1.77 Million | +56.94% |
| 2020-12-31 | $1.13 Million | -0.79% |
| 2019-12-31 | $1.14 Million | -74.57% |
| 2018-12-31 | $4.48 Million | +280.88% |
| 2017-12-31 | $1.18 Million | +75.14% |
| 2016-12-31 | $672.02K | +31.56% |
| 2015-12-31 | $510.80K | +35.31% |
| 2014-12-31 | $377.51K | -45.74% |
| 2013-12-31 | $695.76K | -0.99% |
| 2012-12-31 | $702.74K | -52.58% |
| 2011-12-31 | $1.48 Million | -69.67% |
| 2010-12-31 | $4.89 Million | -25.73% |
| 2009-12-31 | $6.58 Million | +163.36% |
| 2008-12-31 | $2.50 Million | -56.97% |
| 2007-12-31 | $5.81 Million | +37.15% |
| 2006-12-31 | $4.23 Million | -- |